Industrial Policy & Trade Monitor· 2665 actions· ✨ 90 recent

Brazil's federal innovation-financing agency FINEP (Financiadora de Estudos e Projetos), under the MCTI/FNDCT umbrella, published a BRL 300 million (~USD 51.7 million) public call — "Finep Mais Inovação Brasil – Rodada 2 – Saúde" — offering non-repayable economic-subsidy grants for private-sector R&D of innovative products or processes for Brazil's health-industrial complex (pharmaceuticals, health-sector chemical inputs). A minimum BRL 90 million is reserved for projects based in the North, Northeast or Center-West regions. Proposal submission opened 2026-02-06 and runs through 2026-09-18.

The Commonwealth of Pennsylvania, via Governor Josh Shapiro's office and the Department of Community & Economic Development, assembled a $100 million public incentive package — up to $50 million via the PA Edge Tax Credit Program, a $25 million PA SITES (Strategic Investments to Enhance Sites) grant, a $25 million Pennsylvania First grant, and up to $5 million via the Redevelopment Assistance Capital Program (RACP) for workforce development — to secure a $3.5 billion private investment from Eli Lilly and Company, the company's first manufacturing facility in Pennsylvania. The 925,000-square-foot facility will be built at the Fogelsville Corporate Center in Upper Macungie Township, Lehigh County, to produce next-generation weight-loss medicines, creating at least 850 new jobs over five years. It is the largest life-sciences investment in Pennsylvania history.

The European Investment Bank signed a EUR 400 million, seven-year loan agreement with Swedish hygiene and health group Essity on 29 January 2026 (EIB project ref. 20210374, "Essity Health and Hygiene Products RDI") to finance research, development and innovation expenditure at Essity's R&D centres in Sweden, Germany and France over 2025-2028. The financing targets product and process development across Personal Care, Professional Hygiene and medical wound care, with emphasis on replacing fossil-based plastics with bio-based materials, cutting greenhouse-gas emissions and expanding digital manufacturing solutions; roughly 30% of the RDI spend is earmarked for feminine-care and incontinence-product research. Global Trade Alert separately logs the transaction as a "red"-flagged state-linked lending intervention (state act 96020 / intervention 151945).

On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.

The British Business Bank, the UK government's state-owned economic development bank, announced a GBP 50 million cornerstone commitment to Epidarex Capital's new life sciences fund on 20 January 2026. The fund, Epidarex Capital IV, LP, went on to announce a first close of USD 145 million on 27 January 2026, with the Bank joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and other family-office and corporate investors. This is the Bank's second cornerstone commitment to an Epidarex fund, following a GBP 50 million stake in Epidarex Capital III UK, LP in 2020.

China's Ministry of Finance, NDRC, Ministry of Industry and Information Technology, People's Bank of China and National Financial Regulatory Administration jointly issued Cai Jin [2026] No. 4 on 2026-01-19, establishing a central-fiscal loan interest-subsidy scheme for micro, small and medium-sized enterprises (MSMEs) operating in 14 designated industrial-chain and emerging-industry sectors. Eligible loans originated from 2026-01-01 receive a 1.5-percentage-point annual interest subsidy for up to two years, capped at RMB 50 million in principal per enterprise (maximum subsidy RMB 1.5 million per enterprise). The policy is tentatively set to run one year with a possible extension.

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 2, "Several Measures on Focusing on Translational Medicine to Accelerate Industry-Medicine Integration Innovation and Development," effective 30 days after promulgation (4 February 2026 per Global Trade Alert tracking) and valid through 31 December 2027. The measures subsidize cell-and-gene therapy, mRNA, synthetic biology, regenerative medicine and digital-medicine R&D (up to CNY 2m/year per entity), platform/lab construction (up to 30% of investment, capped at CNY 2m), use of the district's translational-medicine national science facility (up to 50% of annual usage fee, capped at CNY 1m), and domestic Class 1 new-drug clinical trials (Phase I up to CNY 2m, Phase II up to CNY 5m, capped at CNY 50m/year per entity), plus annual support for biopharma industrial- park operators (up to CNY 2m/year).

The British Business Bank, the UK government's state-owned economic development bank, took a GBP 10.5 million (USD 13.9 million) equity stake in EpilepsyGTx, a UCL-spinout gene-therapy company, as part of a USD 33 million Series A financing round announced 10 December 2025. The round also included XGEN Venture and an unnamed global biopharmaceutical company; proceeds fund first-in-human Phase 1/2a trials of EpilepsyGTx's lead gene-therapy candidate EPY201 for focal refractory epilepsy.

The European Commission approved German State aid of €47 million to Vetter Pharma, a family-owned contract development and manufacturing organisation (CDMO), to support a new aseptic fill-finish plant for injectable pharmaceuticals in Saarlouis, Saarland. The grant is part of a larger ~€480 million first construction phase of the site, which the Commission cleared under EU State aid rules citing job creation (up to 2,000 positions long-term), regional development in Saarland, and consistency with the EU Pharmaceutical Strategy for Europe's goal of securing affordable-medicines manufacturing capacity in the bloc.

The UK Department of Health and Social Care, delivered via Innovate UK, awarded more than GBP 54 million in government funding across eight R&D projects on 18 November 2025 through the Sustainable Medicines Manufacturing Innovation Programme, matched by more than GBP 20 million from industry (combined GBP 74m+). The programme is funded through the GBP 400 million VPAG Investment Programme, agreed under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), and supports the manufacturing pillar of the UK's Modern Industrial Strategy Life Sciences Sector Plan. Funded projects include anaesthetic gas recovery/recycling (targeting ~GBP 5m annual NHS savings), converting spent nuclear fuel into radionuclide cancer therapies, CAR-T cell manufacturing scale-up (Royal Free Hospital), engineered bacteriophages for antibiotic resistance, and an AstraZeneca-led "Sustainable Future Factory" AI/robotics initiative.

On 12 November 2025 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2025〕12号, "Several Measures of Beijing Dongcheng District on Promoting Science and Technology Innovation Development," effective 12 December 2025 through 31 December 2028. The package tiers cash grants by milestone: up to RMB 100,000 for first-time high-tech-enterprise certification, RMB 1 million for first-to-market new technology/products, RMB 10 million for incubator and specialised industrial-park upgrades, and up to RMB 30 million for "chain-leader" enterprises or innovation-driving market entities judged to have significant regional radiating/spillover effect. Eligible sectors span new-generation information technology, cultural technology, pharmaceuticals and health, intelligent manufacturing, new materials, and green energy/environmental protection.

Russia's federal Industry Development Fund (FRP) disclosed a RUB 950 million (approx. USD 12 million) concessional loan under its "Development Projects" programme to biopharmaceutical company Nanolek LLC, financing purchase of high-tech equipment for Russia's first domestic human papillomavirus (HPV) vaccine production line. The facility, part of a RUB 7.5 billion total investment in the Orichevsky District of Kirov Region, opened 25-29 October 2025 and produces the "Tsegardeks" vaccine at an initial capacity of over 600,000 doses per year, rising to 3-3.5 million doses annually by 2027 with a planned second production line.

The UK Office for Life Sciences (OLS) launched the Life Sciences Large Investment Portfolio (LSLIP), a subsidy scheme worth up to GBP 570 million running from implementation in November 2025 to March 2030. The scheme provides direct grants, capped at GBP 130 million per award, to UK-registered private-sector companies committing to invest GBP 250 million or more over three years in domestic manufacturing or commercial R&D across three subsectors: human medicines (APIs and finished products), medical diagnostics, and MedTech. The scheme was referred to the CMA's Subsidy Advice Unit on 21 August 2025, which published its advisory report on 2 October 2025 ahead of the scheme's launch.

The UK Department for Science, Innovation and Technology and the Office for Life Sciences launched the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot, a GBP 50 million (approx. USD 67.4 million) capital grant scheme for large-scale R&D projects in the life sciences sector. Only projects with total costs of at least GBP 100 million qualify, with grants typically covering 10-20% of total project costs. The pilot runs on a rolling-application basis until 31 March 2028 or until funding is exhausted.

The European Investment Bank (EIB) signed a EUR 400 million loan agreement with Fresenius on 8 September 2025 in Bad Homburg, Germany, to finance research, development and innovation activities and capacity expansion for Fresenius Kabi's manufacturing of biosimilars, generic drugs, infusion therapies, clinical nutrition products, and associated medical devices across EU member states. The financing is explicitly framed by both parties as strengthening the resilience of European pharmaceutical production and security of supply for EU healthcare systems.

The British Business Bank, the UK government's economic development bank, announced an GBP 8 million equity investment into NRG Therapeutics Ltd on 8 September 2025 as part of an oversubscribed GBP 50 million (USD 67 million) Series B financing round. NRG Therapeutics develops small-molecule mitochondrial permeability transition pore (mPTP) inhibitors for neurodegenerative diseases including ALS/MND and Parkinson's. The round was led by SV Health Investors' Dementia Discovery Fund, with participation from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, and existing investors Omega Funds and Brandon Capital; a British Business Bank representative joined NRG's board.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

Wisconsin Governor Tony Evers and the Wisconsin Economic Development Corporation (WEDC) announced on 5 August 2025 a package of up to $100 million in performance-based Enterprise Zone state tax credits to support Eli Lilly and Company's $4 billion expansion of its parenteral (injectable) drug manufacturing site in Bristol, Kenosha County. The credits are split between up to $18 million for job creation and up to $82 million for capital investment, contingent on Lilly creating at least 700 jobs and making at least $2.2 billion in qualifying capital investment, with the allocation period running through 2036.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

The European Investment Bank signed a EUR 150 million loan agreement with Italian pharmaceutical group Alfasigma SpA on 8 July 2025 to finance the company's 2025-2027 research and development programme in rare diseases and specialty care (gastroenterology/hepatology, vascular medicine, rheumatology). The EIB framed the operation as part of its agenda to bolster competitiveness and innovation in the European healthcare sector. Global Trade Alert logged the announcement and implementation date as 27 June 2025 (state-act 92597); the EIB's own press release places the signing on 8 July 2025.

France's Ministry of Agriculture, acting through FranceAgriMer, opened a EUR 45 million call for projects on 30 June 2025 to fund research and development of alternatives to chemical crop protection products (phytopharmaceuticals). The call — part of the PARSADA strategic plan launched in spring 2023 to anticipate a potential EU-level withdrawal of active substances — funds 3-to-5 year projects at 40-100% of eligible costs, capped at EUR 7.5 million per project, across eight agricultural sectors. Applications are accepted on a rolling basis through 31 December 2026.

On 28 May 2025, Brazilian President Lula launched "Chamada Nordeste" in Salgueiro (Pernambuco) — a BRL 10 billion (~USD 1.8bn) public call for structuring investment projects in the nine Northeast states, run jointly by BNDES, Banco do Brasil, Caixa Econômica Federal, Banco do Nordeste (BNB) and Finep, with technical support from Sudene and the Northeast Consortium. It is the largest project call ever run for the region and sits under the federal Nova Indústria Brasil (NIB) industrial-policy umbrella. Eligible business plans (minimum BRL 10 million) cover storage/renewable energy, bioeconomy with a pharmaceuticals focus, green hydrogen, green data centers and the automotive/agricultural-machinery sector, financed via a combination of credit lines, non-reimbursable economic subsidies and equity participation; the proposal deadline was 15 September 2025. Demand vastly exceeded supply: the call drew 245 proposals totalling roughly BRL 127.8 billion — nearly 13 times the initial BRL 10bn envelope — before BNDES approved 189 projects worth BRL 113 billion in follow-on selection rounds.

The UK Department for Science, Innovation and Technology signed a grant agreement with BioNTech UK Ltd. providing up to GBP 129 million in government support over 10 years, underpinning BioNTech's planned GBP 1 billion (USD 1.3 billion) investment in UK research and development over the same period. The funding backs two new R&D hubs: a life-sciences research centre in Cambridge (genomics, oncology, structural biology, regenerative medicine) and an AI hub co-located with BioNTech's planned UK headquarters in London, run by its InstaDeep subsidiary. The government frames the deal as one of the largest single-company investments in UK life-sciences history and part of the Oxford-Cambridge Growth Corridor and Plan for Change industrial strategy.

Bpifrance, France's state-owned public investment bank, took a 1.8% equity stake with board representation in Opella — the Sanofi-spun-off consumer healthcare unit that makes Doliprane (paracetamol) and other OTC brands — as part of the closing of Sanofi's sale of a 50% controlling stake to US private equity firm Clayton, Dubilier & Rice (CD&R). Sanofi retains 48.2%. The stake was widely read domestically as a state sovereignty guarantee attached to a politically contentious foreign takeover of a company regarded as critical to French medicine supply security.

The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.